Epstein-Barr Virus (EBV) Antibodies to Early Antigen-Diffuse [EA(D)], IgG

The Epstein-Barr Virus (EBV) Antibodies to Early Antigen-Diffuse [EA(D)], IgG test aids diagnosis of acute EBV infection (infectious mononucleosis) and assists in determining whether reactivation is occurring. EA(D) IgG typically appears early in primary infection and in most patients becomes nonreactive within six months; continued positivity or reappearance can support reactivation, particularly in immunosuppressed or transplant recipients. The assay is used with viral capsid antigen (VCA) IgM/IgG and EBNA-1 IgG to clarify the stage of infection. This EBV Early Antigen IgG (EA(D) IgG) measurement can also help differentiate causes of acute tonsillopharyngitis and contribute to the workup when a herpesvirus etiology is being considered. It serves as adjunctive or confirmatory testing when initial EBV serology by ELISA yields equivocal findings.

Epstein-Barr virus, a member of the Herpesviridae family, establishes lifelong latency primarily in B lymphocytes and can also infect T cells and epithelial cells. Primary infection is frequent in childhood and often asymptomatic. In adolescents and adults, symptomatic disease commonly manifests as infectious mononucleosis with fever, lymphadenopathy, tonsillopharyngitis, and hepatosplenomegaly, and is accompanied by atypical lymphocytosis on the peripheral smear. Complications of EBV infection may include hepatitis, pneumonia, hemolytic anemia, thrombocytopenia, splenic rupture, myocarditis, and neurologic syndromes. In immunocompromised hosts, EBV reactivation may contribute to lymphoproliferative disease and other EBV-associated malignancies. Serologic patterns assist with staging: VCA IgM and VCA IgG arise early; EBNA-1 IgG appears later and persists as a marker of past infection. EA(D) IgG develops during the acute phase and typically wanes; persistence or renewed detection can support reactivation. This assay provides a qualitative result only—reactivity above the cutoff does not quantify antibody concentration—and results should be interpreted in conjunction with clinical findings and other EBV serologies.